Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010, Article ID 139304, 11 pages
Review Article

Harnessing the Effect of Adoptively Transferred Tumor-Reactive T Cells on Endogenous (Host-Derived) Antitumor Immunity

1Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756, USA
2The Immunology Program, The Wistar Institute, Philadelphia, PA 19104, USA

Received 18 June 2010; Accepted 5 August 2010

Academic Editor: Kurt Blaser

Copyright © 2010 Yolanda Nesbeth and Jose R. Conejo-Garcia. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Adoptive T cell transfer therapy, the ex vivo activation, expansion, and subsequent administration of tumor-reactive T cells, is already the most effective therapy against certain types of cancer. However, recent evidence in animal models and clinical trials suggests that host conditioning interventions tailored for some of the most aggressive and frequent epithelial cancers will be needed to maximize the benefit of this approach. Similarly, the subsets, stage of differentiation, and ex vivo expansion procedure of tumor-reactive T cells to be adoptively transferred influence their in vivo effectiveness and may need to be adapted for different types of cancer and host conditioning interventions. The effects of adoptively transferred tumor-reactive T cells on the mechanisms of endogenous (host-derived) antitumor immunity, and how to maximize their combined effects, are further discussed.